ArticleFrontiers in immunology2025
Integrative multi-omics analysis identifies a PTM-related immune signature and IRF9 as a driver in ccRCC.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PTM encoding: decoding the mechanisms of exercise-induced metabolic memory through spatiotemporal modification networks.Frontiers in sports and active living · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) exhibits marked heterogeneity and variable benefit from immune checkpoint inhibitors (ICIs). Post-translational modifications (PTMs) regulate immune signaling and tumor behavior, yet PTM-informed biomarkers for ccRCC remain underexplored. Methods: We intersected immune-related genes, PTM-related genes, and differentially expressed genes in TCGA-KIRC to derive candidates and built a prognostic model across TCGA and E-MTAB-1980 using multiple algorithms, selecting a random survival forest-based post-translational modification-related signature (PTMRS) with the best performance. Prognostic value and independence were evaluated by time-dependent ROC, Kaplan-Meier, and multivariate Cox analyses. Tumor immune context was profiled by immune infiltration scores, immune checkpoints, and TIDE to infer dysfunction/exclusion and ICI response. Genomic features (driver mutations, pathway alterations, tumor mutational burden) and an external ICI cohort (IMvigor210) were analyzed. Single-cell RNA-seq with CellChat, trajectory, and UCell assessed cell-cell communication and PTMRS distribution across immune subsets. Experimental validation included IHC and qPCR of IRF9, loss- and gain-of-function assays (Transwell, wound healing, CCK-8, colony, EdU), and molecular dynamics to explore IRF9 compound binding. Results: We established a five-gene PTMRS that robustly stratified prognosis in training, testing, and external cohorts and remained an independent predictor. High-PTMRS tumors displayed immunosuppressive features, including greater infiltration of Tregs/MDSCs/macrophages, higher expression of immunosuppressive checkpoints, and elevated TIDE scores with lower predicted ICI responsiveness. High PTMRS associated with alterations in oncogenic pathways and higher TMB. In IMvigor210, high PTMRS linked to inferior outcomes and non-response. Single-cell analyses showed PTMRS enrichment in Tregs and exhausted CD8 Conclusion: PTMRS is a PTM-informed immune signature that reflects an immunosuppressive tumor microenvironment, improves prognostic stratification, and indicates ICI benefit in ccRCC. Experimental data pinpoint IRF9 as a functional driver and potential therapeutic target within this PTM-immunity axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.